NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症治療的NDDS的全球市場

NDDS in Cancer Therapy

出版商 Global Industry Analysts, Inc. 商品編碼 997598
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
癌症治療的NDDS的全球市場 NDDS in Cancer Therapy
出版日期: 2021年04月01日內容資訊: 英文 112 Pages
簡介

全球癌症治療的NDDS的市場規模,預計在分析期間(2020年∼2027年)將以19.7%的年複合成長率增長,從2020年的73億美元,到2027年達到255億美元。

本報告所分析的市場區隔之一的栓塞粒子部門,在分析期間中預計將以21%的年複合成長率增長,達到19億美元。

本報告提供全球癌症治療的NDDS市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Celgene Corporation
  • Galen Limited
  • Merrimack Pharmaceuticals, Inc.
  • Samyang Biopharmaceuticals Corp.
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:46公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP15942

Abstract:

Global NDDS in Cancer Therapy Market to Reach $25.5 Billion by 2027

Amid the COVID-19 crisis, the global market for NDDS in Cancer Therapy estimated at US$7.3 Billion in the year 2020, is projected to reach a revised size of US$25.5 Billion by 2027, growing at aCAGR of 19.7% over the period 2020-2027. Embolization Particles, one of the segments analyzed in the report, is projected to record 21% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nanoparticles segment is readjusted to a revised 19.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.2 Billion, While China is Forecast to Grow at 19.3% CAGR

The NDDS in Cancer Therapy market in the U.S. is estimated at US$2.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2027 trailing a CAGR of 19.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.5% and 16.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR.

Select Competitors (Total 46 Featured) -

  • Celgene Corporation
  • Galen Limited
  • Merrimack Pharmaceuticals, Inc.
  • Samyang Biopharmaceuticals Corp.
  • Spectrum Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for NDDS in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for NDDS in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 7: USA Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 8: USA 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • CANADA
    • TABLE 9: Canada Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 10: Canada 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • JAPAN
    • TABLE 11: Japan Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 12: Japan 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • CHINA
    • TABLE 13: China Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 14: China 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • EUROPE
    • TABLE 15: Europe Current & Future Analysis for NDDS in Cancer Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 16: Europe 7-Year Perspective for NDDS in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 17: Europe Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Europe 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • FRANCE
    • TABLE 19: France Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: France 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • GERMANY
    • TABLE 21: Germany Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Germany 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • ITALY
    • TABLE 23: Italy Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Italy 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 25: UK Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: UK 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 27: Rest of Europe Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Rest of Europe 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 29: Asia-Pacific Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Asia-Pacific 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 31: Rest of World Current & Future Analysis for NDDS in Cancer Therapy by Segment - Embolization Particles and Nanoparticles - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Rest of World 7-Year Perspective for NDDS in Cancer Therapy by Segment - Percentage Breakdown of Value Sales for Embolization Particles and Nanoparticles for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46